UNSPSC 51292401: Bifemelane

This classification denotes an antidepressive agent with the molecular formula C18H23NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z4501GN13G, chemically known as 1-butanamine, n-methyl-4-(2-(phenylmethyl)phenoxy)-, hydrochloride but generally known as bifemelane, which bears US NIH Compound Identifier 2377. Bifemelane most often comes in base and hydrochloride forms. European Medicines Agency schedules Bifemelane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05827MIG.

UNSPSC 51292401 Bifemelane (Commodity) does not align with the recent state and local procurement activity tagged under this code. The three opportunities posted between January and June 2026 solicit naloxone and drug deactivation systems, therapeutic pharmacy initiatives, and generic multi-source pharmaceuticals and OTC products — none of which are bifemelane, a pharmaceutical compound used in neurological therapy. State and local governments do procure pharmaceuticals, but the specific commodity code appears to mismatch the actual buying activity in the recent record.

The opportunities that do appear under the code reflect broader pharmaceutical and medical product procurement across different issuing bodies. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (due July 26, 2023). The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be distributed across state and local facilities in Minnesota and Oregon. The mix of issuing bodies — a county health department, a state health agency, and a multistate cooperative — suggests that pharmaceutical procurement spans local health authorities and state-level consolidated purchasing programs. Given the mismatch between the bifemelane commodity code and the naloxone, generic pharmaceuticals, and direct-supply initiatives actually being solicited, this code shows little relevant recent activity for vendors focused on the specific pharmaceutical it nominally describes.